A successful negotiation on medical insurance of diabetes drugs secret price exposure?

On November 28, the state health insurance bureau announced the results of 2019 health insurance negotiation 97 varieties (48 domestic drugs and 49 imported drugs) from 62 enterprises (42 domestic drug enterprises and 20 transnational drug enterprises) were successfully negotiated, including 70 new drugs, with an average price decrease of 60.7%, 27 renewal contracts, and an average price decrease of 26.4% For the specific price reduction of each drug, the state health insurance bureau allows enterprises to apply for price confidentiality, so as to win the lowest possible price for patients, but not all enterprises have applied for price confidentiality According to the data released by the health insurance bureau, there are 50 public payment standards for drugs, 47 enterprises have applied for price confidentiality, among which, Hangzhou, China, the United States and East China successfully negotiated Acarbose chewable tablets (50mg, trade name: carbopin) produced by pharmaceutical Co., Ltd (Hangzhou Zhongmei Huadong, a wholly-owned subsidiary of Huadong pharmaceutical, a listed company) also applied for price confidentiality However, recently, the centralized drug purchase platform of Yunnan Province released a batch of drug-related change information publicity According to the publicity, Hangzhou Zhongmei Huadong applied for the price reduction of acarbose chewable tablets, from 2.6877 yuan / tablet to 1.1 yuan / tablet (in June this year, Hangzhou Zhongmei Huadong also proposed the application of active price reduction in Heilongjiang, from 80.5 yuan / box to 43.46 yuan / box, equivalent to 1.45 yuan / tablet), which also means The price of a box of acarbose chewable tablets decreased from 80.63 yuan to 33 yuan, a decrease of 59.11% When applying for price reduction at this time, it is easy to associate the latest payment standard price of medical insurance with either the price reduction range (not much different from the average price reduction range of negotiated drugs) or the time node It is understood that acarbose is a kind of α - glucosidase inhibitor and the first oral antidiabetic product in China It can competitively inhibit glucosidase, inhibit the decomposition of starch into glucose, and then reduce the absorption of glucose in the intestine, reduce postprandial hyperglycemia, and have good safety Because the main food of Chinese people is rice and pasta with high starch content, plus the original In the early stage, Bayer company, the research manufacturer, actively promoted the market, and acarbose was widely used in China According to the 2017 version of China's guidelines for the prevention and treatment of type 2 diabetes, acarbose was listed as the first-line drug for type 2 diabetes, and was successively included in the 2017 version of the national medical insurance catalog (Class A) and the 2018 version of the national basic drug catalog.